Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA7 | P43166 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312865 | 0.87 | KDM4E (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2952986 | 0.86 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL630337 | 0.85 | SLC6A3 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11801731 | 0.85 | KMT2A (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12121707 | 0.84 | GABRA1 (0.62) | SLC6A3SLC6A4GABRA1GABRG2GABRB3 | |
| SCHEMBL7563000 | 0.84 | SLC6A3 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL818748 | 0.83 | PTGS2 (0.59) | SLC6A3SLC6A4GABRA1GABRG2GABRB3 | |
| SCHEMBL6776148 | 0.83 | HDAC7 (0.67) | SLC6A3SLC6A4GABRA1GABRG2GABRB3 | |
| SCHEMBL2952989 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18143540 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-0986384-A4 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-0970703-B1 | USE OF METAL CHELATING AGENTS TO STABILIZE PREPARATIONS CONTAINING INTERFERON | SCHERING CORP (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-0873123-B1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| EP-0777495-B1 | STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS | SCHERING CORP (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0986384-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0970703-A1 | Stable, aqueous alfa interferon solution formulations | SCHERING CORPORATION (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5935566-A | AVOIDING VISIBLE PARTICULATE MATTER FORMATION IN AN AQUEOUS ALFA INTERFERON FORMULATION HAVING DISODIUM DIHYDROGEN ETHYLENEDIAMINETETRAACETATE AS A CHELATING AGENT, A SORBITAN MONO-9-OCTADECENOATE POLYOXYETHYLENE GLYCOL STABILIZER | SCHERING CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1998050030-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050029-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5766582-A | STORAGE STABILITY; MIXTURE WITH BUFFER, STABILIZER AND CHELATE COMPOUND | SCHERING CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0777495-A1 | STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS | SCHERING CORPORATION (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996011018-A1 | STABLE, AQUEOUS ALFA INTERFERON SOLUTION FORMULATIONS | SCHERING CORPORATION (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | CA12 4688/4885CA1 4388/4885CA2 2452/4885 |
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | CA12 2602/4885CA1 2409/4885CA2 1546/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | CA12 1562/4885CA1 557/4885CA2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.